ARTICLE | Company News
Axerion Therapeutics, AstraZeneca deal
May 7, 2012 7:00 AM UTC
Axerion granted AstraZeneca's MedImmune LLC biologics unit exclusive rights to develop and commercialize a preclinical mAb for Alzheimer's disease that inhibits the interaction between prion protein...